BioMarin to buy Prosensa, experimental muscular dystrophy drug in out-of-character deal

Rare disease drug developer BioMarin Pharmaceutical Inc. will pay up to $840 million for Dutch biopharmaceutical company Prosensa Holding NV, a company whose drug for a form of muscular dystrophy could be rejected by U...